维普期刊资源整合服务平台（V6.5）

208篇 您的检索式：作者名="Boige V"

选中清除导出查看参考文献查看引证文献引用追踪共11页首页上一页第1页下一页末页 /11 跳转

	题名	作者	年代	出处	被引量
1	Treatment of advanced pancreatic cancer显示文摘	Ducreux M Boige V Malka D	2007	Seminars in oncology2007，34，11：	1
2	KRAS mutations as an in- dependent prognostic factor in patients with advanced colorectal cancer treated with eetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，：	1
3	Immunogenic death of colon cancer cells treated with oxaliplatin显示文摘	Tesniere A Schlemmer F Boige V Kepp O Martins I Ghiringhelli F	2010	Oncogene2010，29，：	1
4	PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer显示文摘	Manceau G Marisa L Boige V	2015	Cancer Med2015，4，3：	1
5	Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors显示文摘	Aparicio T Boige V Sabourin JC	2004	Eur J Surg Oncol2004，30，10：	1
6	Prognostic factors after surgery of primary respectable gastrointestinal stromal tumors显示文摘	Aparicio T Boige V Sabourin JC	2004	Eur J Surg Oncol2004，30，10：	1
7	KRAS mutations as an independent prognostic factor in pa- tients with advanced colorectal cancer treated with cetuximab 显示文摘	Lievre A Bachet J B Boige V Cayre A Le Corre D Buc E	2008	J Clin Oncol2008，26，：	1
8	Therapeutic strategies using VEGF inhibitors in colorectal cancer显示文摘	Boige V Malka D Ducreux M	2005	Bull Cancer2005，92，2：	1
9	KRAS mutations as an in- dependent prognostic factor in patients with advanced colorec- tal cancer treated with cetuximab 显示文摘	Lavre A Baehet JB Boige V	2008	J Clin Oncol2008，26，3：	1
10	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，：	1
11	K-RAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab显示文摘	LIEVRE A BACHET J B BOIGE V	2008	J Clin 379 Oncol2008，26，3：	1
12	Final results of a randomized trial comparing preoperative FP to surgery alone in adenocarcinoma of stomach and low esophagus: FNLCC ACCO- RD07-FFCD 9703 trial显示文摘	Boige V Pignon J Saint-Aubert B	2007	J Clin Oncol2007，25，16：	1
13	ERCC1 codon 115 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer显示文摘	Viguier J Boige V Miquel C	2005	Clin Cancer Res2005，11，17：	1
14	Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors 显示文摘	Aparicio T Boige V Sabourin JC	2004	Eur J Surg Oncol2004，30，10：	1
15	Multicentre phase Ⅱ study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma显示文摘	Raymond E Fabbro M Boige V	2003	Ann Oncol2003，14，4：	1
16	Perioperative chemotherapy com- pared with surgery alone for resectable gastroesophageal adenocarcino- ma : an FNCLCC and FFCD muhicenter phase ]II trial 显示文摘	Ychou M Boige V Pignon JP	2011	J Clin On- col2011，29，13：	1
17	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with eetuximab显示文摘	Lievre A Bachet J B Boige V	2008	J Clin Onco12008，26，3：	1
18	Gemcitabine plus oxalipaltin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC):results of a phase Ⅱ smdy显示文摘	Louafi S Boige V Ducreux	2007	Cancer2007，109，7：	1
19	Finalresultsofarandomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P)to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE):FNLCCACCORD07-FFCD 9703 trial显示文摘	Boige V Pignon J Saint-Aubert B		0，，18：	1
20	Immunogenic death of colon cancer cells treated with oxaliplatin显示文摘	TESNIERE A SCHLEMMER F BOIGE V	2010	Oncogene2010，29，4：	1

返回顶部每页显示：

共11页首页上一页第1页下一页末页 /11 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示